Transformational Health team provides critical insights into the Asian specialty generics market with this research service, highlighting growth opportunities, selected countries’ biopharmaceutical environment, and significant R&D, regulatory, and infrastructure reforms influencing its growth. The report examines similarities and contrasts between various Asian countries in specialty generics R&D, manufacturing, adoption, and access.
Specialty generics do not have a commonly accepted definition, often used interchangeably as complex generics.Specialty pharmaceuticals are often large, injectable, protein-based molecules produced through a biotechnology process.
But they may also be small molecules produced through traditional pharmaceutical manufacturing methods.Specialty generics offer lucrative market opportunities to Asian drug manufacturers to increase profit margins by developing innovative, value-added alternatives of existing drugs to offset traditional generics’ shrinking margins in developed countries. The focus on improving the R&D landscape, especially for biologics, will attract global biopharmaceuticals to Asia due to the inherent advantage of a large patient pool and low-cost development and manufacturing.This report reviews drivers propelling specialty generics adoption in these countries. For example, the rising prevalence of chronic diseases such as diabetes and cancer, where specialty drugs primarily drive treatment, will drive the demand for economic and easy-to-administer generic formulations to improve access. Self?administered medications using new drug delivery systems such as nasal sprays, autoinjectors, pen injectors, prefilled syringes, and needle-free injectors offer convenience that will drive the specialty generics demand. Specialty generics development provides competitive differentiation to companies compared to traditional generics. Compared to the 505(b)(1) pathway for new drug approval (NDA), the 505(b)(2) pathway in the US offers faster approval, lower risk, and market exclusivity from 3 to 7 years in some instances when coupled with the correct development and regulatory strategies.
Our reports have been used by over 10K customers, including:
Market Overview: The global chitosan market reached a value of US$ 2.49 Billion in 2020. Chitosan is a naturally occurring deacetylated chitin which is extracted from the hard outer-skeleton or shells of shrimps, crabs and lobsters, along with mushrooms and yeasts. It is primarily used as an ingredient in medicines...
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 184.108.40.206) - Drugs in Development, 2021 Summary According to the recently published report ’Tyrosine Protein Kinase JAK1 - Drugs in Development, 2021’; Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 220.127.116.11) pipeline Target constitutes...
Preparative And Process Chromatography Market Size, Share & Trends Analysis Report By Product (Process Chromatography, Preparative Chromatography), By Type, By End Use, And Segment Forecasts, 2021 - 2028 Preparative And Process Chromatography Market Growth & Trends The global preparative and...
The global autoinjectors market is projected to reach USD 104.9 billion by 2025 from USD 46.0 billion in 2020, at a CAGR of 17.9% from 2020 to 2025. Market growth is largely driven by the growing prevalence of targeted therapies, the rising incidence of anaphylaxis, rising preference for self-administration of drugs, usability advantages,...
The Global Pharmaceutical CDMO Market was valued USD 160.12 billion in 2020, and it is expected to reach USD 236.61 billion by 2026, registering a CAGR of 6.5%, during the period of forecast period (2021-2026). The CMO/CDMO service sector is uniquely positioned to address some of the challenges that drug developers are facing amid the COVID-19...
The global pharmaceutical contract development and manufacturing market is projected to reach USD 146.1 billion by 2025 from USD 100.7 billion in 2020, at a CAGR of 7.7% during the forecast period. Market growth is driven mainly by factors such as rising demand for generics, increasing investments in pharmaceutical R&D, and investments in...
The Transdermal Skin Patches market is expected to register a CAGR of about 4.78% during the forecast period with a revenue of approximately USD 7244.33 million in 2020 and expected to reach USD 9572.34 million by 2026. The COVID-19 outbreak across the world is expected to have a positive impact on the transdermal skin patches market,...
The Veterinary Pain management market was valued at USD 1,197 million in 2020, and it is expected to reach USD 1,910 million in 2026, registering a CAGR of nearly 6.30% during the forecast period. The global outbreak of COVID-19 has impacted all industries including veterinary pain medicine. Pet parents are advised to keep a safe distance...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.